Answers are grounded in this paper and cite their sources.
// Xingshun Qi 1, 2, * , Yan Zhao 2, 3, * , Hongyu Li 1, * , Xiaozhong Guo 1 , Guohong Han 2 1 Department of Gastroenterology and Meta-analysis Study Interest Group, General Hospital of Shenyang Military Area, Shenyang, 110840 China 2 Department of Liver Diseases and Digestive Interventional Radiology, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi’an, 710032 China 3 Department of Gastroenterology, First Affiliated Hospital of the Medical College, Xi’an Jiaotong University, Xi’an, 710000 China * Co-first authors, these authors contributed equally to this work Correspondence to: Xingshun Qi, email: xingshunqi@126.com Xiaozhong Guo, email: guo_xiao_zhong@126.com Guohong Han, email: guohhan@126.com Keywords: hepatocellular carcinoma, treatment, management, meta-analysis, systematic review Received: February 19, 2016 Accepted: April 11, 2016 Published: May 04, 2016 ABSTRACT This paper aims to systematically review the major findings from meta-analyses comparing different treatment options for hepatocellular carcinoma (HCC). A total of 153 relevant papers were searched via the PubMed, EMBASE, and Cochrane library databases. They were classified according to the mainstay treatment modalities (i.e., liver transplantation, surgical resection, radiofrequency ablation, transarterial embolization or chemoembolization, sorafenib, and others). The primary outcome data, such as overall survival, diseases-free survival or recurrence-free survival, progression-free survival, and safety, were summarized. The recommendations and uncertainties regarding the treatment of HCC were also proposed.
No takes yet. Share an insight, caveat, or question.
Qi et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: